Replies to post #8272 on Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

There is no patent cliff. The way their contracts are set up, they continue to make royalties (at the same rate as before patent expiration) for minimum of 10 years if there is a coformulation patent (which there is for all existing programs.)

The only exception is Faspro, but even with that, the royalties will continue to flow to Halozyme but at a discounted rate.

You don’t have to take my word for it. Read/listen to the January financial update.

Then again, I am sure you already knew this and you “patent cliff” remark is to spread misinformation and scare the uninformed.